GPRC5D

SHANGHAI, NANJING, China and SAN JOSE, Calif., March 28, 2025 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative cell therapies and biologics, today announced that the Pharmaceutical Administration Bureau of the Macao Special Administrative Region (ISAF) has approved the New Drug Application (NDA) for Equecabtagene Autoleucel. This treatment is indicated for adult patients with relapsed or refractory multiple myeloma (R/RMM) who have received three or more lines of prior therapies, including at least one proteasome inhibitor and an immunomodulatory agent. This is the first NDA approval for Equecabtagene Autoleucel outside Mainland China . Equecabtagene Autoleucel (trade name: FUCASO) was approved by China's National Medical Products Administration (NMPA) on June 30, 2023, for treating adult patients with relapsed or refractory multiple myeloma (R/RMM) who have received three or more lines of prior therapies, including at least one proteasome inhibitor and an immunomodulatory agent. On January 29 and February 14, 2025, the NDA for this product for the above indications was formally accepted by the Health Sciences Authority of Singapore and the Department of Health of Hong Kong, China, respectively. The Macau NDA approval is based on data from the pivotal FUMANBA-1 trial (CTR20192510, NCT05066646), a China-based, multi-site, Phase I/II registrational study evaluating the efficacy and safety of equecabtagene autoleucel in patients with relapsed/refractory multiple myeloma (R/R MM). The results demonstrated that equecabtagene autoleucel achieves outstanding efficacy and a favorable safety profile. Ms. Zhang Jinhua, Founder, Chairperson, and CEO of IASO Biotherapeutics, stated: "We are delighted that the New Drug Application (NDA) for equecabtagene autoleucel has been approved by the Macau Drug Administration—the product's first NDA approval outside Mainland China, marking a significant milestone. Through our innovative 'Manufactured in Nanjing, Supplied Globally' model, we will ensure timely access to this CAR-T therapy for multiple myeloma patients in Macau. In December last year, we successfully delivered our Nanjing-manufactured CAR-T therapy to patients in Hong Kong through the Named Patient Program (NPP). Subsequently, in January and February of this year, the NDAs for equecabtagene autoleucel were officially accepted by the Singapore Health Sciences Authority and the Hong Kong Department of Health, respectively. We are actively collaborating with regulatory authorities to advance the approval processes and look forward to delivering clinical benefits to patients in these regions at the earliest opportunity. Meanwhile, IASO Bio remains committed to expanding the global footprint of our CAR-T therapies, dedicated to providing more treatment options for multiple myeloma patients worldwide." About Multiple Myeloma （ MM) Multiple myeloma (MM) is the second most common hematological malignancy globally. According to Globocan data, the global incidence of multiple myeloma in 2022 was 1.8 per 100,000 people, with a 5-year prevalence of 6.8 per 100,000. Despite progress in current anti-myeloma treatments, MM remains largely incurable with multiple relapses and tendency to develop refractoriness to several drug classes, presenting a major therapeutic challenge. Thus, there is an unmet need for new treatment options beyond these current anti-myeloma therapies for the treatment of relapsed or refractory MM, capable of achieving deep and durable responses. About Equecabtagene Autoleucel Equecabtagene Autoleucel is an innovative fully human anti-BCMA CAR-T cell therapy which uses lentivirus as a gene vector to transfect autologous T cells. The CAR contains a fully human scFv, CD8a hinge and transmembrane, and 4-1BB co-stimulatory and CD3ζactivation domains. Based on rigorous molecular structure screening and comprehensive in vitro and in vivo functional evaluations, FUCASO demonstrates rapid and potent efficacy, accompanied by exceptional long-term persistence in vivo, enabling patients to achieve higher and deeper responses, providing continuous protection and care for patients with multiple myeloma. About IASO Bio IASO Bio Founded in 2017, IASO Bio is a leading biopharmaceutical company specializing in the discovery, development, manufacturing, and commercialization of cutting-edge cell therapies and biologics. Initially focused on treatments for blood cancers, the company has strategically expanded into autoimmune diseases. IASO Bio boasts a robust drug development platform, encompassing early discovery to clinical trials, regulatory approval, and commercialization. The company is advancing a diverse pipeline of over 10 innovative products. Notably, Equecabtagene Autoleucel (FUCASO), the world's first fully human CAR-T therapy developed by IASO Bio was approved by Chinese National Medical Products Administration (NMPA) in June 2023 for the treatment of relapsed and/or refractory multiple myeloma (R/R MM) who received ≥3 lines of prior therapies containing at least one proteasome inhibitor and an immunomodulatory agent. relapsed/refractory multiple myeloma (R/RMM) in patients at the fourth line and beyond. This product is also in Phase III clinical trials for second and third-line multiple myeloma (MM) and has received Investigational New Drug (IND) approvals in both China and US for autoimmune diseases. Meanwhile, the dual-target (CD19/CD22) product, CT120, for lymphoma is entering Phase II clinical trials. Additionally, RD118, another product targeting GPRC5D for the treatment of R/R MM, has received IND approval in China. In addition to CAR-T therapies, IASO Bio is advancing IASO-782, a fully human anti-CD19 monoclonal antibody. This product has secured IND approvals in China and USA for several autoimmune diseases, with plans to explore additional autoimmune indications. IASO Bio has established multiple global collaborations and licensing agreements with leading cell therapy companies, such as Sana Therapeutics, Cabaletta Bio, and Umoja Biopharma, underscoring its superior technology platform and commitment to next-generation cell therapies. With a strong management team, a robust pipeline, high-standard manufacturing and advanced clinical development capabilities, the company is well-positioned to drive innovation. It remains committed to accelerating the development of transformative therapies that address unmet medical needs for patients worldwide. For more information, please visit or . SOURCE IASO Bio WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

In January 2025, the pharmaceutical collaborations and transactions showcased a diversified trend of development, ranging from multinational pharmaceutical corporations to startup biotech enterprises. Each party is actively exploring new partnership models and technological platforms. Initially, the collaboration between Simcere Zaiming and AbbVie marks their dedication to combating the complex disease of multiple myeloma. The SIM0500 project, based on T-cell engaging bispecific antibody technology, not only demonstrates the application potential of cutting-edge scientific research but also brings new hope for patients. Moreover, Daiichi Sankyo's acquisition of the TA-MUC1 antibody gatipotuzumab from Glycotope highlights the focus on antibody-drug conjugate (ADC) therapy, providing more effective solutions for cancer treatment. Concurrently, the strategic cooperation between Gilead Sciences and LEO Pharma focuses on the development of STAT6 inhibitors, indicating that the field of inflammatory diseases is becoming the next hot spot for research. By developing oral STAT6 inhibitors, the partners aim to overcome the limitations of current treatments reliant on injectable biologics, offering a more convenient therapeutic option. Additionally, the partnership agreement between Harbour BioMed and Windward Bio on HBM9378/SKB378 further reflects the high level of global attention to unmet medical needs in inflammatory diseases such as asthma, as well as the rise of Chinese biopharmaceutical firms in the international market. 1.Simcere Zaiming and AbbVie Jointly Develop New Trispecific Antibody SIM0500  On January 13, 2025, Simcere Pharmaceutical Group Limited (HKEX code: 2096) through its subsidiary Simcere Zaiming, together with AbbVie Inc. (NYSE code: ABBV), announced a licensing agreement choice to co-develop a novel trispecific candidate antibody named SIM0500. This drug is intended for patients with relapsed or refractory multiple myeloma (MM), currently undergoing Phase I clinical trials in China and the USA. SIM0500 is a humanized trispecific antibody specially targeting GPRC5D, BCMA, and CD3, independently developed by Simcere Zaiming using its T-cell engager bispecific antibody technology platform. The uniqueness of this antibody lies in its low affinity/high-targeting activation CD3 engagement arm and binding sites targeting two tumor antigens, GPRC5D and BCMA, capable of generating potent T-cell cytotoxicity against multiple myeloma cells through various anti-tumor mechanisms. The objective of this collaboration is to jointly advance the research and development of SIM0500, providing new therapeutic options for patients with multiple myeloma. As per the terms of the agreement, Simcere Zaiming will receive an upfront payment from AbbVie and is eligible to receive option fees and milestone payments totaling up to $1.055 billion, in addition to tiered royalties on net sales outside of Greater China. AbbVie will receive tiered royalties on net sales in Greater China. This collaboration not only strengthens both parties' capabilities in research and treatment of hematologic malignancies but also offers potential solutions for the significant unmet medical needs of multiple myeloma patients. Through this partnership, the two companies will share resources and technology to accelerate the clinical development process of SIM0500. 2.Daiichi Sankyo Acquires Glycotope’s TA-MUC1 Antibody for $132.5 Million, Accelerating Development of DS-3939 ADC Therapy  On January 13, 2025, Daiichi Sankyo Company announced that it would pay Glycotope GmbH $132.5 million to acquire the full intellectual property rights to the tumor-associated mucin-1 (TA-MUC1) antibody gatipotuzumab. This transaction is based on a licensing agreement signed by both parties in 2018, which granted Daiichi Sankyo the exclusive rights to develop and commercialize gatipotuzumab as an antibody-drug conjugate (ADC) globally. The transaction involves DS-3939, an ADC under development by Daiichi Sankyo, which utilizes the company's proprietary DXd ADC technology. DS-3939 comprises a humanized anti-TA-MUC1 antibody linked to a topoisomerase I inhibitor payload (exatecan derivative DXd) via a tetrapeptide cleavable linker. DS-3939 is currently in Phase 1/2 clinical trials for the treatment of various advanced solid tumors, including non-small cell lung cancer, breast cancer, urothelial cancer, ovarian cancer, biliary cancer, and pancreatic cancer. As a tumor-specific transmembrane glycoprotein overexpressed in most human epithelial cancers, TA-MUC1 represents an attractive target for cancer therapy. The purpose of this acquisition is to strengthen Daiichi Sankyo's leadership position in the ADC field and to further enrich its product line. With the complete intellectual property of gatipotuzumab, Daiichi Sankyo can more freely advance the development of DS-3939, offering new therapeutic options for cancer patients with unmet medical needs. This transaction not only signifies Daiichi Sankyo's continued commitment to investing in innovative cancer therapies but also lays the groundwork for potential future market breakthroughs. 3.Gilead and LEO Pharma Partner to Expedite Development of Oral STAT6 Inhibitor  On January 11, 2025, Gilead Sciences and LEO Pharma announced the establishment of a strategic partnership to expedite the development of LEO Pharma’s small molecule oral STAT6 program, which holds potential for treating inflammatory diseases. STAT6, a transcription factor required for signaling by the IL-4 and IL-13 cytokines, plays a crucial role in Th2-mediated inflammation such as atopic dermatitis, asthma, and chronic obstructive pulmonary disease (COPD). The aim of the collaboration is to provide an oral alternative to patients currently requiring injectable biologic treatments. According to the terms of the partnership agreement, Gilead will acquire development rights to LEO Pharma's comprehensive preclinical oral STAT6 small molecule inhibitors and targeted protein degraders, and will be responsible for further development of these oral projects. Concurrently, LEO Pharma will focus on developing topical formulations of potential STAT6 inhibitors and retain exclusive global rights to them. Additionally, LEO Pharma will have rights to co-commercialize oral medications for dermatological treatments outside the United States. The transaction involves up to $1.7 billion, including an upfront payment of $250 million, along with tiered royalties based on product sales. This partnership not only strengthens Gilead's position in the field of inflammatory disease treatment but also reflects LEO Pharma’s commitment to propelling innovation in dermatology through scientific research. The collaboration is expected to provide new treatment options for patients with chronic inflammatory diseases, especially those seeking more convenient treatment modalities. Gilead hopes to explore the potential of the STAT6 pathway through this collaboration, while LEO Pharma aims to accelerate the development of the STAT6 program and maximize its application potential. 4.Harbour BioMed has reached an agreement with Windward Bio to jointly advance the fully human anti-TSLP antibody HBM9378/SKB378 On January 10, 2025, Harbour BioMed, a global biopharmaceutical company specializing in innovative antibody therapies in oncology and immunology, together with Kelun-Botai, announced that they have entered into a licensing agreement with Windward Bio AG for the co-developed anti-TSLP (thymic stromal lymphopoietin) fully human monoclonal antibody HBM9378/SKB378. According to the terms of the agreement, Windward Bio has secured exclusive rights to research, develop, manufacture, and commercialize HBM9378/SKB378 globally, excluding Greater China, certain Southeast Asian, and Western Asian countries. The deal is valued up to $970 million, including an upfront payment and near-term milestone payments totaling $45 million that incorporate both cash and a share in the equity of Windward Bio's parent company. Additionally, Harbour BioMed and Kelun-Botai will be entitled to receive further payments if Windward Bio undergoes a change of control or enters into re-licensing agreements with other third parties. This partnership provides significant financial backing and is hoped to expedite the development process of HBM9378/SKB378 in meeting the underserved medical needs on a global scale. Through this collaboration, Harbour BioMed and Kelun-Botai aim to leverage Windward Bio's expertise and resources to further advance HBM9378/SKB378, which promises new treatment options for patients with inflammatory diseases such as asthma and chronic obstructive pulmonary disease. The uniquely designed trispecific antibody provides an extended half-life, significantly reducing the dosing frequency, improving patient compliance, and is administered subcutaneously enhancing convenience for patients. This cooperation not only demonstrates the innovative capabilities of the companies in the biopharmaceutical field but also marks a significant step in their international strategy, laying a solid foundation for long-term strategic growth. 5.Eternal Immunotherapies Enters into Strategic Collaboration with Dropshot Therapeutics On January 9, 2025, Ethernal Immunotherapies NV (“Ethernal”), a leader in mRNA and lipid nanoparticle (LNP) technology, announced a strategic multitarget collaboration with Dropshot Therapeutics (“Dropshot”), a biotechnology company focused on the treatment of cardiac and renal diseases. The partnership accelerates the development of RNA-based therapeutic approaches through the joint exploration of new drug candidates for multiple indications. Under the terms of the agreement, Ethernal will receive an upfront payment and research funding, with the potential for milestone payments during development and tiered royalties following commercialization, potentially totaling $950 million. The core of this collaboration leverages Ethernal's proprietary mRNA and LNP technology platforms, which enable precise RNA therapy delivery and expression to targeted organs and cell types. Dropshot contributes its deep expertise and technical know-how in the cardiac and renal disease arena, particularly in the cutting-edge exploration of delivering RNA payloads using LNPs. This collaboration not only propels the progression from pre-clinical animal studies to human clinical trials but also reflects the companies’ shared vision and commitment to developing innovative therapies. For Ethernal, this partnership forges its position as a leader in nucleic acid-based drug development technologies and offers an opportunity to apply its technology in new therapeutic areas, improving patient quality of life. For Dropshot, working with Ethernal enables it to better address significant unmet medical needs in cardiac and renal diseases, advancing the development of innovative therapies. As emphasized by Ethernal's CEO, Bernard Sagaert, and Dropshot's CEO, Marijn Dekkers, the collaboration marks a concerted effort by both companies to develop transformative treatments for complex and challenging health conditions. 6.Mabworks Biotech has licensed its preclinical product MIL116 to Climb Bio, strengthening its layout in the field of immune kidney diseases Mabworks Biotech announced a collaboration agreement with Climb Bio on January 10, 2025, and signed related contracts. According to the agreement, Mabworks will grant Climb Bio the rights to use its patents and proprietary technologies related to MIL116, an innovative APRIL antibody in preclinical development, granting the latter development, manufacturing, and sales rights globally, excluding Greater China. This collaboration involves a substantial amount, with the total potential payments reaching up to $893 million, including an upfront payment of $9 million, cumulative development milestone payments of up to $51.75 million, and sales milestone payments of up to $832 million. Additionally, Mabworks will receive a percentage of the net sales globally as royalties and other potential licensing payments. For Mabworks, this partnership not only brings significant capital inflow but also marks an important milestone in its overseas collaborations for in-house developed products, showcasing the company's strong R&D capabilities and global vision in the treatment of immune-mediated kidney diseases. Through cooperation with Climb Bio, Mabworks can further advance the development process of MIL116, accelerate the drug's entry into clinical trials, and ultimately benefit a broad patient population with IgA nephropathy. For Climb Bio, acquiring MIL116 (referred to as CLYM116 in its pipeline) represents a significant step towards becoming a leader in innovative therapies for immune-mediated diseases. Given that IgA nephropathy is a major cause of global glomerulonephritis and there is a substantial unmet medical need, research on the APRIL pathway inhibition mechanism is expected to bring revolutionary treatment methods for this disease. 7.Alpha Cognition and CMS secure a $44 million agreement to advance Zrevyl® in the Asian market for the treatment of mild to moderate Alzheimer's disease On January 8, 2025, Alpha Cognition, Inc., a biopharmaceutical company focused on developing new therapies for debilitating neurodegenerative diseases, announced an exclusive licensing agreement with CMS. The agreement pertains to Alpha Cognition’s next-generation acetylcholinesterase inhibitor, ZUNVEYL (benzgalantamine), an orally administered drug approved by the FDA for the treatment of mild to moderate Alzheimer’s disease. According to the terms of the agreement, the total amount is $44 million, including an upfront payment of $6 million and subsequent installment payments, development, and commercial milestones. Additionally, Alpha Cognition is eligible to receive royalties on the net sales of ZUNVEYL in Asia (excluding Japan), Australia, and New Zealand. CMS will take on the full responsibilities for regulatory approval, development, manufacturing, and commercialization of ZUNVEYL in these regions. This collaboration leverages CMS’s expertise and resources in the Chinese market to accelerate the launch of ZUNVEYL in the specified regions, meeting the substantial demand for Alzheimer’s treatment medications in those areas. 8.Candid Therapeutics Reaches Collaboration Agreement with WuXi Biologics on Tri-specific T Cell Engagers Candid Therapeutics, Inc., a clinical-stage biotechnology company focused on the development of T cell engagers for treating autoimmune and inflammatory diseases, has announced a significant agreement with WuXi Biologics. Under this agreement, Candid will obtain exclusive global rights to a preclinical tri-specific T cell activator discovered using WuXi Biologics' proprietary WuXiBodyTM platform. This collaboration will accelerate Candid's development in the B-cell depletion therapy area, specifically for T cell engagers (TCEs) targeting BCMA, CD20, and CD19. Candid plans to complete the IND-enabling studies by the first half of 2026, setting the stage for the first human trials. Additionally, the agreement includes an upfront payment to WuXi Biologics and eligibility for up to $925 million in developmental and sales milestone payments, plus royalties on post-commercialization sales. For Candid, this agreement not only strengthens its leadership in the T cell engager field but also provides robust resource support to advance the development of novel therapies. For WuXi Biologics, this collaboration showcases the powerful capabilities of its WuXiBodyTM platform, especially in discovering complex tri-specific antibodies, and further establishes it as a preferred partner for next-generation biologic drug development. 9.Merck Acquires WuXi Biologics' Dundalk Vaccine Facility for €500 Million, Boosting Global Vaccine Production Capacity On January 6, 2025, WuXi Biologics’ indirect wholly-owned subsidiary, Yaoming Haide Ireland, reached an agreement with Merck (known as MSD outside the USA and Canada) to sell its vaccine facility in Ireland. Valued at approximately €500 million, this transaction is part of Merck's long-term development strategy in Ireland and significantly expands its local presence. The objective of this transaction is to bolster Merck's position in global vaccine production and to meet the growing market demand by increasing production capacity. Notably, this deal follows Merck's previously announced investment of €1 billion in its facilities in Carlow and Dunboyne, demonstrating the company's commitment to the Irish market. The entire handover process is expected to be completed in the first half of 2025, at which point Merck will formally take over the operations of the Dundalk facility and begin integrating this new capacity into its global network. Summary The pharmaceutical collaborations and transactions in January 2025 showed several significant characteristics: First, there was a diversification of cooperation forms, covering multiple aspects from early-stage R&D tech licensing to market expansion of mature products. Second, the targets of these collaborations were clear, whether aiming for innovative therapies for specific diseases or enhancing the efficacy of existing treatments, all parties were committed to addressing unmet medical needs. Third, there was a noticeable globalization trend, with frequent cross-national collaborations highlighting the importance of resource sharing and collaborative innovation on a global scale. In terms of trends, anti-cancer drugs remained a focal point for investment and collaboration, particularly with advances in immunotherapies, bispecific antibodies, and Antibody-Drug Conjugate (ADC) technologies, which provided new treatment directions for refractory diseases such as multiple myeloma. Additionally, more attention started to be paid to inflammatory diseases such as asthma and atopic dermatitis, indicating that besides traditional oncology, chronic disease management was gradually becoming another crucial research and development focus. Moreover, the strengthening of vaccine production was an unignorable trend, especially critical in enhancing production capabilities in the face of global public health challenges. Looking ahead, the goals of these collaborations and transactions were not only to accelerate the development process of new drugs but also to optimize the entire industry chain, including all aspects from basic research to clinical trials, and through to production and commercialization. By establishing extensive and in-depth cooperative relationships, companies could fully leverage their respective strengths, achieving mutually beneficial outcomes. Additionally, this also indicated that the future pharmaceutical market would increasingly focus on the development of personalized treatment plans and ongoing improvements in patient experiences, thereby truly implementing a patient-centered value orientation. How to get the latest progress on drug deals? If you would like to access the latest transaction event information, you can click on the 'Deal' module from the homepage of the Synapse database. Within the Deal module, you can search for global pharmaceutical transaction information using labels such as Drugs, Organization, Target, Drug Type, Deal Date.  Furthermore, you can obtain the original link to the transaction coverage by clicking on the "Deal Name." In the analysis view, you can see the most active assignors, assignees, popular targets, and other dimensions of analysis, as well as the distribution of research and development statuses at the time of the transaction, to help you better understand the search results. The Synapse database also supports the ability to view current transactions from the dimension of "drugs" (by selecting "drugs" from the "Adjust Dimension" dropdown menu above). Targeting transactions involving renowned pharmaceutical companies that are of interest to the industry, such as Merck, Roche, etc., Synapse has identified a group of "leading companies" through drugs that have achieved global sales exceeding 1 billion US dollars in 2022. Transactions involving drugs from these leading companies can be filtered by clicking on the "Leading Company" tag on the left-hand side. In addition to the drug transaction module, you can also view related transaction history on the drug detail page and the institution detail page. Click on the image below to explore new pharmaceutical funding transactions! 

As the global pharmaceutical market continues to expand and China's biopharmaceutical industry rapidly advances, in January 2025, several companies announced collaborations with international pharmaceutical giants to launch a series of new drugs globally. From Innovent Biologics' collaboration with Roche on IBI3009 to Lepu Biopharma's licensing agreement with ArriVent for MRG007, these actions highlight the significant role Chinese biopharmaceuticals play in the globalization process. 1.Innovent Biologics joins forces with Roche to make IBI3009 a revolutionary force in treating small cell lung cancer On January 2, 2025, Innovent Biologics announced it had granted Roche the global exclusive rights to the new drug IBI3009. According to the terms of the agreement, Innovent Biologics has transferred to Roche the exclusive global rights to develop, manufacture, and commercialize IBI3009. The parties plan to jointly advance the early developmental stages of this antibody-drug conjugate (ADC), with Roche leading the subsequent clinical development. As part of the deal, Innovent Biologics will receive an upfront payment of $80 million, with the potential to earn up to $1 billion in milestone payments and royalties based on sales. IBI3009 is a next-generation ADC developed by Innovent Biologics, targeting Delta-like ligand 3 (DLL3), a marker that is lowly expressed in normal tissues but highly expressed in specific cancer types such as small cell lung cancer (SCLC). By specifically binding to DLL3, IBI3009 can precisely target cancer cells without harming healthy cells, providing new hope for treatment in advanced SCLC patients. This drug utilizes Innovent Biologics' proprietary new class topoisomerase I inhibitor platform for efficient payload delivery and intracellular toxin release in tumor cells, showing promising antitumor activity and safety. 2.WuXi Biologics partners with Candid Therapeutics to advance a novel trispecific antibody therapy using the WuXiBody™ platform On January 7, 2025, WuXi Biologics entered into a landmark research services collaboration agreement with Candid Therapeutics, marking a new phase in their partnership in the innovation of therapeutic development. Under the agreement, Candid will obtain global rights to a trispecific antibody developed on WuXi Biologics' WuXiBody™ platform, currently in preclinical development, designed to target three different antigen sites: BCMA, CD20, and CD19. BCMA is highly expressed in hematologic malignancies such as multiple myeloma, while CD20 and CD19 are primarily found on the surface of B cells, playing crucial roles in various B-cell-related cancers including non-Hodgkin's lymphoma. This antibody can not only recognize and bind to specific antigens on cancer cells but also activate the patient's immune system, particularly T cells, thereby more effectively clearing tumor cells. WuXi Biologics' WuXiBody™ platform offers unique advantages for this trispecific antibody, enabling simultaneous targeting of tumor cell antigens CD20 and CD19 as well as the T-cell surface activation molecule BCMA, promoting close contact between T cells and tumor cells, enhancing T-cell-mediated cytotoxicity. Furthermore, through this triple targeting mechanism, the antibody may also inhibit the ability of tumor cells to evade immune surveillance, further enhancing therapeutic efficacy. The financial terms of this collaboration are also notable, with WuXi Biologics receiving an undisclosed upfront payment, eligible for subsequent development and sales milestone payments totaling up to $925 million, plus royalties on post-commercialization sales. 3.Duality Biologics Reaches Dual-Specificity ADC Collaboration Agreement with Avenzo Therapeutics On January 8, 2025, Duality Biologics announced an exclusive licensing agreement with Avenzo Therapeutics, granting Avenzo the global rights (excluding Greater China) to develop, manufacture, and commercialize the dual-specificity antibody-drug conjugate (ADC) EGFR/HER3, DB-1418/AVZO-1418. According to the agreement terms, Duality Biologics will receive an upfront payment of $50 million and is eligible for up to $1.15 billion in developmental, regulatory, and commercial milestones, in addition to royalties on sales in Avenzo's designated regions. DB-1418/AVZO-1418 is an innovative dual-specificity ADC that targets EGFR and HER3, which are overexpressed antigens in various cancer types. By targeting both receptors, DB-1418 enhances selective recognition of cancer cells and promotes more effective internalization, delivering its cytotoxic payload – a topoisomerase I inhibitor – directly into the tumor cells to disrupt their DNA replication process, leading to cancer cell death. The ADC leverages Duality Biologics’ proprietary DIBAC platform, ensuring both efficient targeting and stable cargo-carrying capabilities of the antibody, overcoming resistance issues common with traditional single-target therapies. 4.Sciwind Biosciences and Verdiva Bio Seal Major Agreement to Propel Innovation in Metabolic Disease Therapeutics On January 10, 2025, Sciwind Biosciences announced a global development and commercialization license and partnership agreement with Verdiva Bio Limited, focusing on innovative therapies in the cardiovascular metabolic disorder sector. A key product under this collaboration is Ecnoglutide Oral, a potentially first-in-class medication in Phase II clinical trial preparation that requires only once-weekly dosing. As a GLP-1 receptor agonist, Ecnoglutide mimics the action of endogenous GLP-1 by activating the glucagon-like peptide-1 receptor (GLP-1R) which is prevalent in multiple organs including the pancreas, gastrointestinal tract, and heart. Activation of GLP-1R promotes insulin secretion, inhibits glucagon release, and slows gastric emptying, thereby aiding in blood sugar control and weight reduction. Moreover, Ecnoglutide possesses cAMP bias, which may offer unique advantages in activating downstream signaling pathways. Additionally, the partnership agreement includes two amylin receptor agonists, one in oral form and the other as a subcutaneous injection. Amylin, secreted by β-cells alongside insulin, assists in postprandial glucose regulation by delaying gastric emptying, reducing food intake, and lowering postprandial glucose peaks. These amylin receptor agonists are designed to complement the effects of GLP-1 receptor agonists, particularly in terms of weight reduction and improved glucose control. By acting directly on the gastrointestinal tract and through central nervous system mechanisms regulating appetite, co-utilizing amylin with GLP-1 offers a potentially more effective and comprehensive metabolic disease management strategy. This partnership is valued at up to $2.47 billion, including nearly $70 million upfront and up to $2.4 billion in potential development, regulatory, and commercialization milestone payments. Further, Sciwind Biosciences will receive royalties on post-commercialization sales. This substantial financial support not only underscores Verdiva Bio's confidence in the market potential of these candidate drugs but also provides robust financial backing to Sciwind Biosciences to expedite the progress of other projects in its development pipeline. 5. Keymed Biomedical’s CD38 Monoclonal Antibody CM313 On January 10, 2025, Keymed Biomedical announced an exclusive licensing agreement with Timberlyne Therapeutics for the global rights (excluding Mainland China, Hong Kong, Macau, and Taiwan) to CM313, a humanized monoclonal antibody targeting CD38 developed in-house. CM313 is an innovative therapeutic agent that specifically binds to and eliminates tumor cells expressing the CD38 glycoprotein, particularly long-lived plasma cells (LLPCs), thereby preventing antibody-mediated platelet destruction and restoring normal platelet production and function. Additionally, CM313 has the ability to modulate immune cell activity, making it a promising candidate for the treatment of relapsed/refractory multiple myeloma, lymphoma, and other autoimmune diseases. Its mechanism of action extends beyond direct induction of tumor cell apoptosis, also involving indirect tumor cell killing via antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and antibody-dependent cellular phagocytosis (ADCP). Under the terms of the agreement, Keymed Biomedical will receive an upfront and near-term payment of $30 million and will become the largest shareholder of Timberlyne, holding a 25.79% equity stake. Furthermore, upon achieving certain sales and development milestones, Keymed is eligible to receive up to an additional $337.5 million, as well as tiered royalties based on net sales. Notably, Timberlyne has successfully completed a $180 million Series A financing round, attracting investments from prominent institutions such as Bain Capital Life Sciences and Venrock Healthcare Capital Partners. 6. Kelun Botai and Harbour BioMed Partner for Global Expansion of TSLP Monoclonal Antibody SKB378/HBM9378 On January 10, 2025, Kelun Botai and Harbour BioMed jointly announced an exclusive licensing agreement with Windward Bio AG for SKB378/HBM9378, a monoclonal antibody targeting thymic stromal lymphopoietin (TSLP), which they co-developed. SKB378/HBM9378 is a fully human monoclonal antibody designed to inhibit TSLP-mediated signaling by blocking the interaction between TSLP and its receptor, thereby reducing inflammatory responses. The drug has already completed a Phase I clinical trial in China for moderate-to-severe asthma, demonstrating good safety and preliminary efficacy. Under the terms of the agreement, Kelun Botai and Harbour BioMed will receive up to $970 million in upfront and milestone payments from Windward Bio, along with tiered royalties ranging from single-digit to double-digit percentages based on net sales. The upfront and near-term payments total $45 million, consisting of both cash consideration and equity in Windward Bio’s parent company. This collaboration follows a NewCo model, meaning that Windward Bio will assume full responsibility for the global (excluding Greater China and select Southeast and West Asian countries) research, development, manufacturing, and commercialization of SKB378/HBM9378. With further clinical development plans underway, particularly in chronic obstructive pulmonary disease (COPD), SKB378/HBM9378 has the potential to become a novel treatment option for this serious respiratory disease. 7. Simcere Zaiming and AbbVie Join Forces to Advance a New Breakthrough in Multiple Myeloma Treatment On January 13, 2025, Simcere Zaiming entered into a significant development and option licensing agreement with AbbVie, a global pharmaceutical leader. This collaboration focuses on SIM0500, a GPRC5D/BCMA/CD3 trispecific antibody independently developed by Simcere Zaiming. Currently in Phase I clinical trials in both China and the United States, SIM0500 has also been granted Fast Track designation by the U.S. Food and Drug Administration (FDA). As a humanized trispecific antibody targeting multiple myeloma, SIM0500 simultaneously binds to GPRC5D, BCMA, and CD3 on T cells. This multi-target approach enhances tumor cell selectivity and cytotoxicity while improving the safety and efficacy of treatment. Under the terms of the agreement, Simcere Zaiming will receive an upfront payment from AbbVie and is eligible for up to $1.055 billion in option and milestone payments. Additionally, Simcere Zaiming will receive tiered royalties based on net sales of SIM0500 outside Greater China, while AbbVie will be entitled to tiered royalties on net sales within the Greater China region. This agreement not only provides Simcere Zaiming with direct financial benefits but also enables the company to share in the global commercial success of SIM0500. 8. Bispecific Antibody ICP-B02 (CM355): InnoCare Pharma and Keymed Biomedical Collaborate to Pioneer a New Frontier in Tumor Immunotherapy On January 20, 2025, InnoCare Pharma and Keymed Biomedical jointly announced a significant licensing agreement with Prolium Bioscience, granting Prolium the rights to develop and commercialize ICP-B02 (CM355), a bispecific antibody. ICP-B02 is an innovative drug designed to simultaneously recognize and bind to CD20-positive tumor cells and CD3-positive T cells. This dual-targeting mechanism enables ICP-B02 to guide the immune system’s T cells toward tumor cells and activate them to effectively eliminate cancer cells through T cell-dependent cytotoxicity (TDCC). Currently, ICP-B02 is undergoing Phase I/II clinical trials in China, primarily targeting relapsed or refractory non-Hodgkin lymphoma (NHL), including follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). Under the terms of the agreement, the two companies will receive payments totaling up to $520 million, including upfront and near-term payments, as well as additional payments upon achieving specified clinical development, regulatory, and commercialization milestones. Additionally, they will retain a minority equity stake in Prolium Bioscience and are entitled to tiered royalties based on future net sales of the product. Prolium has obtained the rights to develop, register, manufacture, and commercialize ICP-B02 in non-oncology indications worldwide and in oncology indications outside Asia. 9. Lepu Biopharma and ArriVent Collaborate to Advance the Globalization of the MRG007 Antibody-Drug Conjugate On January 22, 2025, Lepu Biopharma entered into an exclusive global licensing agreement with ArriVent BioPharma, granting ArriVent the rights to develop, manufacture, and commercialize the innovative antibody-drug conjugate (ADC) MRG007 outside the Greater China region. MRG007 is designed for the treatment of gastrointestinal cancers. Under the agreement, ArriVent gains exclusive rights to MRG007 in all territories outside Mainland China, Hong Kong, Macau, and Taiwan. This collaboration represents a significant milestone for Lepu Biopharma, not only facilitating the advancement of MRG007’s clinical development but also marking an important step in the company’s global expansion strategy. According to the agreement, Lepu Biopharma will receive a total of $47 million in upfront and near-term milestone payments, with additional development, regulatory, and sales milestone payments of up to $1.16 billion. Furthermore, Lepu Biopharma is entitled to tiered royalties based on net sales of MRG007 outside Greater China. This financial arrangement ensures short-term capital inflow for the company while laying a solid foundation for its future success. Moreover, it reflects the international market’s recognition and confidence in MRG007’s potential, signaling that this drug could become a key treatment option for gastrointestinal cancers. Summary January 2025 witnessed a series of significant events in the international expansion of Chinese innovative drugs. These strategic collaborations not only provided substantial financial returns and growth opportunities for Chinese pharmaceutical companies but also expanded global treatment options for patients. For instance, Innovent Biologics accelerated the development of its novel small-cell lung cancer ADC, IBI3009, through a partnership with Roche. Similarly, DualityBio licensed the global rights of its EGFR/HER3 bispecific ADC, DB-1418, to Avenzo Therapeutics, further strengthening its presence in the oncology sector. Additionally, Sciwind Biosciences’ collaboration with Verdiva Bio focused on metabolic diseases, demonstrating the innovative capabilities of Chinese companies beyond oncology. Notably, the financial terms behind these agreements are equally impressive. For example, Keymed Biomedical secured up to $337.5 million in additional payments, while Lepu Biopharma stands to receive up to $1.16 billion in milestone payments. These transactions not only highlight the global market’s high regard for the potential of Chinese innovative drugs but also underscore the strong demand from multinational corporations for high-quality, high-potential pharmaceutical assets when seeking collaboration opportunities. How to get the latest progress on drug deals? If you would like to access the latest transaction event information, you can click on the 'Deal' module from the homepage of the Synapse database. Within the Deal module, you can search for global pharmaceutical transaction information using labels such as Drugs, Organization, Target, Drug Type, Deal Date.  Furthermore, you can obtain the original link to the transaction coverage by clicking on the "Deal Name." In the analysis view, you can see the most active assignors, assignees, popular targets, and other dimensions of analysis, as well as the distribution of research and development statuses at the time of the transaction, to help you better understand the search results. The Synapse database also supports the ability to view current transactions from the dimension of "drugs" (by selecting "drugs" from the "Adjust Dimension" dropdown menu above). Targeting transactions involving renowned pharmaceutical companies that are of interest to the industry, such as Merck, Roche, etc., Synapse has identified a group of "leading companies" through drugs that have achieved global sales exceeding 1 billion US dollars in 2022. Transactions involving drugs from these leading companies can be filtered by clicking on the "Leading Company" tag on the left-hand side. In addition to the drug transaction module, you can also view related transaction history on the drug detail page and the institution detail page. Click on the image below to explore new pharmaceutical funding transactions!